Additionally, a reduction in the level of caspase 3, the crucial mediator of programmed cell death, with infliximab administration was a prominent finding, and this is in agreement with that of Saritemur et al. (2015), who proved that infliximab administration at a dose of (5 mg/kg, i.p.)decreased caspase 3 expression in a rodent model of glycerol-contrast-induced nephropathy (Saritemur et al. 2015). Here, CASP3 is linked to kidney disorder.